Search results
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Motley Fool· 1 year agoWhat happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were...
US FDA approves Novo Nordisk's therapy for rare genetic condition
Reuters via Yahoo News· 8 months agoThe once-monthly injection, to be sold under the brand name Rivfloza, is approved for use in people...
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Zacks via Yahoo Finance· 9 months agoArbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies...
Insider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc
GuruFocus.com via Yahoo Finance· 9 months agoOn September 18, 2023, Christopher Anzalone, the CEO of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR),...
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 9 months agoAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call Transcript September 12, 2023...
Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today
Motley Fool· 2 years agoShares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market...
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 months agoStrengths: Pioneering RNAi therapeutics with a robust product portfolio and strategic...
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Motley Fool· 1 year agoBiotech stocks got pummeled in 2022. Valuations across the small- and mid-cap biotech landscape...
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares
GuruFocus.com via Yahoo Finance· 3 months agoArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the...
Novartis warns U.S. plan to curb drug prices could hit key research
Reuters via Yahoo News· 1 year agoU.S. government plans to rein in drug prices could discourage work in some of Novartis's most...